相关实验视频

Updated: May 7, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

阿尔茨海默病病理学的小鼠非转基因模型:关注风险因素

Maricarmen Hernández-Rodríguez¹, Juan Manuel Vega López², Martín Martínez-Rosas³

¹Laboratorio de Cultivo Celular, Neurofarmacología y Conducta, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Mexico City 11340, Mexico.

|March 28, 2025

概括

阿尔茨海默病 (AD) 研究经常使用转基因模型. 本综述探讨了非转基因模型,比如那些由链毒素或衰老引起的模型,以更好地评估阿尔茨海默病的治疗方法.

科学领域:

神经科学是一个神经科学.
病理学病理学病理学
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默病 (AD) 是一种主要的神经退行性疾病,具有未满足的治疗需求.
目前的AD研究严重依赖于粉样β (Aβ) 转基因模型,治疗成功有限.
关键的AD病理包括Aβ斑块,神经纤维状结和神经炎症.

研究的目的:

对阿尔茨海默病研究的非转基因模型进行批判性审查.
评估由链毒素,胺,衰老,金属和饮食等药物诱导的模型的实用性.
加强这些模型在评估阿尔茨海默病治疗干预措施时的应用.

主要方法:

对阿尔茨海默病非转基因模型现有研究的文献综述.
分析特定药物 (链毒素, scopolamine,金属等) 诱导的模型. 和条件 (衰老,机械压力,饮食).
评估这些模型如何模仿AD病理和风险因素.

主要成果:

非转基因模型提供了对阿尔茨海默病的复杂病理学的补充见解,超出了以Aβ为中心的观点.
由各种因素诱导的模型可以回顾AD的关键特征,如神经炎症和认知缺陷.
这些模型对于评估针对主要AD风险因素的干预措施是有价值的.

结论:

非转基因模型是阿尔茨海默病研究和治疗策略评估的实际工具.
扩大这些多样化的模型的使用可以加速开发有效的AD治疗方法.
对诱导的非转基因模型的进一步研究可以改善临床前AD药物发现.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的疾病粉样蛋白β 粉样蛋白非转基因模型的非转基因模型

更多相关视频

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...